MetaCap

Caribou Biosciences (CRBU) vs Elutia (ELUT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elutia (ELUT) has outperformed Caribou Biosciences (CRBU) over the past year, gaining 52.6% versus a loss of 83.8%. Over five years, ELUT leads with a -82.8% price change compared with -98.4% for CRBU. Elutia is the larger company by market cap ($40.0 million vs $30.7 million), about 1.3 times the size, while Caribou Biosciences is growing revenue faster (+11.7% vs -15.0%).

Elutia converts more of its revenue into profit, with a net margin of 434.2% versus -1327.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRBU-83.75%ELUT+52.56%
+116%+12%-93%
Nov 21, 20251 yearNov 20, 2026
CRBU-98.66%ELUT-84.48%
+47%-29%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRBU versus ELUT key metrics
MetricCRBUELUT
Share price$0.2843$0.9001
Market cap$30.71M$39.96M
1-day change-8.44%+11.12%
YTD return-82.12%+29.88%
1-year return-83.75%+52.56%
5-year return-98.39%-82.76%
EPS (TTM)$-1.03$-0.68
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$11.16M$12.29M
Revenue growth (YoY)+11.66%-15.03%
Net income (latest FY)$-148.13M$53.38M
Gross margin—53.66%
Operating margin-1329.37%-218.91%
Net margin-1327.40%434.23%
52-week high$2.49$1.39
52-week low$0.2819$0.50
Distance from 52-week high-88.58%-35.01%
Analyst consensusbuystrong_buy
Avg. price target upside+1922.51%+455.49%
Average volume2.87M185.17K
Shares outstanding108.04M44.40M
Employees9725
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELUT has outperformed CRBU by 136.3 percentage points over the past year.
  • Elutia is more profitable, keeping 434.2 cents of every revenue dollar as net income versus -1327.4 cents for Caribou Biosciences.
  • Caribou Biosciences grew revenue faster in its latest fiscal year (+11.66% vs -15.03%).

About Caribou Biosciences

CRBU stock →

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees

About Elutia

ELUT stock →

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees

CRBU vs ELUT FAQ

Which is bigger, Caribou Biosciences or Elutia?

Elutia (ELUT) is larger, with a market capitalization of $39.96M compared with $30.71M for Caribou Biosciences (CRBU).

Which stock has performed better over the past year, CRBU or ELUT?

ELUT returned +52.56% over the past 12 months, compared with -83.75% for CRBU (price return, excluding dividends). Past performance does not predict future results.

Are Caribou Biosciences and Elutia in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons